Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.
Derek Wainwright, Rimas Lukas, Lijie Zhai, Kristen Lauing, Miri Kim, Taylor Koch, Manon Penco-Campillo, Prashant Bommi, Karan Dixit, Priya Kumthekar and 20 more
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Amy Beth Heimberger · 2018 to 2026
$21.4M
IDO1 and Immunotolerance in GlioblastomaR01NS097851 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHILTZ, GARY E, WAINWRIGHT, DEREK ALAN · 2016 to 2025
$4.6M
Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and MalignancyR01NS102669 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HORBINSKI, CRAIG MICHAEL · 2017 to 2021
$1.7M
The interaction of IDO and Tregs Leads to Immunosuppression in GliomaR00NS082381 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2014 to 2016
$735k
Aging, immunosenescence and glioblastomaK02AG068617 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2020 to 2024
$688k
The interaction of IDO and Tregs Leads to Immunosuppression in GliomaK99NS082381 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2013 to 2014
$173k
The role of IDO and Th17 in an experimental mouse model of gliomaF32NS073366 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2011 to 2012
$86k
The 10x Chromium System for High-Throughput Single Cell GenomicsS10OD025120 · OD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WANG, XINKUN · 2019 to 2019
This phase I trial evaluated the IDO1 enzyme inhibitor, BMS-986205, with radiation (RT) and nivolumab treatment in newly diagnosed patients with GBM IDHwt. Cohort A received RT + nivolumab with escalating BMS-986205 doses in MGMT unmethylated GBM patients. Cohort B received the highest dose of BMS-986205 with nivolumab and standard RT/temozolomide (TMZ) TMZ in MGMT methylated GBM patients. The treatments were found to be safe and tolerable. The median overall survival was 11.5 (95% CI: 3.71, 33.8) and 26.9 months (95% CI: 8.94-NR) while the 2-year survival rates were 33% (95% CI: 10.3%, 58.8%) and 60% (95% CI: 12.6%, 88.2%) for MGMT unmethylated and methylated GBM, respectively. Longer patient survival was associated with higher CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205. · full record | OpenQuestion